Literature DB >> 10073958

Relative contribution of insulin and its precursors to fibrinogen and PAI-1 in a large population with different states of glucose tolerance. The Insulin Resistance Atherosclerosis Study (IRAS).

A Festa1, R D'Agostino, L Mykkänen, R P Tracy, D J Zaccaro, C N Hales, S M Haffner.   

Abstract

Hyperinsulinemia is associated with the development of coronary heart disease. However, the underlying mechanisms are still poorly understood. Hypercoagulability and impaired fibrinolysis are possible candidates linking hyperinsulinism with atherosclerotic disease, and it has been suggested that proinsulin rather than insulin is the crucial pathophysiological agent. The aim of this study was to investigate the relationship of insulin and its precursors to markers of coagulation and fibrinolysis in a large triethnic population. A strong and independent relationship between plasminogen activator inhibitor-1 (PAI-1) antigen and insulin and its precursors (proinsulin, 32-33 split proinsulin) was found consistently across varying states of glucose tolerance (PAI-1 versus fasting insulin [proinsulin], r=0.38 [r=0.34] in normal glucose tolerance; r=0.42 [r=0.43] in impaired glucose tolerance; and r=0.38 [r=0.26] in type 2 diabetes; all P<0.001). The relationship remained highly significant even after accounting for insulin sensitivity as measured by a frequently sampled intravenous glucose tolerance test. In a stepwise multiple regression model after adjusting for age, sex, ethnicity, and clinic, both insulin and its precursors were significantly associated with PAI-1 levels. The relationship between fibrinogen and insulin and its precursors was significant in the overall population (r=0.20 for insulin and proinsulin; each P<0.001) but showed a more inconsistent pattern in subgroup analysis and after adjustments for demographic and metabolic variables. Stepwise multiple regression analysis showed that proinsulin (split products) but not fasting insulin significantly contributed to fibrinogen levels after adjustment for age, sex, clinic, and ethnicity. Decreased insulin sensitivity was independently associated with higher PAI-1 and fibrinogen levels. In summary, we were able to demonstrate an independent relationship of 2 crucial factors of hemostasis, fibrinogen and PAI-1, to insulin and its precursors. These findings may have important clinical implications in the risk assessment and prevention of macrovascular disease, not only in patients with overt diabetes but also in nondiabetic subjects who are hyperinsulinemic.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10073958     DOI: 10.1161/01.atv.19.3.562

Source DB:  PubMed          Journal:  Arterioscler Thromb Vasc Biol        ISSN: 1079-5642            Impact factor:   8.311


  56 in total

1.  Increased PAI-1 in females compared with males is protective for abdominal aortic aneurysm formation in a rodent model.

Authors:  Paul D DiMusto; Guanyi Lu; Abhijit Ghosh; Karen J Roelofs; Gang Su; Yunge Zhao; Christine L Lau; Omar Sadiq; Brendan McEvoy; Adriana Laser; Jose A Diaz; Thomas W Wakefield; Peter K Henke; Jonathan L Eliason; Gilbert R Upchurch
Journal:  Am J Physiol Heart Circ Physiol       Date:  2012-02-03       Impact factor: 4.733

2.  High prevalence of nonalcoholic fatty liver in patients with idiopathic venous thromboembolism.

Authors:  Matteo Nicola Dario Di Minno; Antonella Tufano; Anna Rusolillo; Giovanni Di Minno; Giovanni Tarantino
Journal:  World J Gastroenterol       Date:  2010-12-28       Impact factor: 5.742

Review 3.  Mechanisms, significance and treatment of vascular dysfunction in type 2 diabetes mellitus: focus on lipid-regulating therapy.

Authors:  Richard J Woodman; Gerard T Chew; Gerald F Watts
Journal:  Drugs       Date:  2005       Impact factor: 9.546

Review 4.  Adipocyte-derived hormones, cytokines, and mediators.

Authors:  Cristina M Rondinone
Journal:  Endocrine       Date:  2006-02       Impact factor: 3.633

5.  The determinants of plasma plasminogen activator inhibitor-1 levels differ for American and Japanese men aged 40-49.

Authors:  Tomoko Takamiya; Takashi Kadowaki; Wahid R Zaky; Hirotsugu Ueshima; Rhobert W Evans; Tomonori Okamura; Atsunori Kashiwagi; Yasuyuki Nakamura; Yoshiyuki Kita; Russell P Tracy; Lewis H Kuller; Akira Sekikawa
Journal:  Diabetes Res Clin Pract       Date:  2005-12-01       Impact factor: 5.602

6.  Metabolic syndrome and sleep apnea.

Authors:  I Kostoglou-Athanassiou; P Athanassiou
Journal:  Hippokratia       Date:  2008-04       Impact factor: 0.471

7.  Distribution and correlates of the metabolic syndrome in adults living in the San Juan Metropolitan Area of Puerto Rico.

Authors:  Cynthia M Pérez; Ana P Ortiz; Manuel Guzmán; Erick Suárez
Journal:  P R Health Sci J       Date:  2012-09       Impact factor: 0.705

Review 8.  Lipid abnormalities in the metabolic syndrome.

Authors:  Eliot A Brinton
Journal:  Curr Diab Rep       Date:  2003-02       Impact factor: 4.810

Review 9.  The metabolic syndrome: time for a critical appraisal. Joint statement from the American Diabetes Association and the European Association for the Study of Diabetes.

Authors:  R Kahn; J Buse; E Ferrannini; M Stern
Journal:  Diabetologia       Date:  2005-09       Impact factor: 10.122

10.  Inflammation-induced atherosclerosis as a target for prevention of cardiovascular diseases from early life.

Authors:  Roya Kelishadi
Journal:  Open Cardiovasc Med J       Date:  2010-02-23
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.